MedTrace Logo

Clinical Study to Evaluate Tear Characteristics Following Acute TrueTear™ Use

NCT03274999 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2021-03-08

Study results available
· View outcomes & findings →

Summary

This study will evaluate the change in tear meniscus height (TMH) produced by intranasal stimulation with TrueTear™ compared with the same device applied extranasally (control).

Conditions

  • Dry Eye Syndromes

Interventions

DEVICE

TrueTear™ Application

Intranasal and extranasal application of TrueTear™ device for approximately 3 minutes at Day 0 and Day 14.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Clinical Director · Allergan, plc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-18
Primary Completion
2017-11-09
Completion
2017-11-09
FDA Device
Yes

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03274999 on ClinicalTrials.gov